RATIONALE: This literature review compares the reported efficacy of tiotropium and leukotriene receptor antagonists (LTRAs) as add-on to ICS in children and adolescents with asthma. METHODS: We searched PubMed for manuscripts comparing LTRAs with placebo, as add-on to ICS, for > _4 weeks in patients with asthma aged 5-18 years, published post-July 2014 (studies published prior were included within two systematic reviews). Results were compared with data from tiotropium trials in pediatric patients. RESULTS: We included two systematic reviews with meta-analyses (Zhao et al. 2015, a network meta-analysis of 35 trials; Castro-Rodriguez et al. 2010, a review including five studies relevant to this analysis). A literature search identified one additional relevant LTRA RCT (Stelmech et al. 2015; n576). Four tiotropium trials were included: two compared tiotropium with placebo as add-on to at least ICS (Hamelmann et al. 2016; Vogelberg et al. 2018); two compared tiotropium with placebo as add-on to ICS plus > _1 additional controller (Hamelmann et al. 2017; Szefler et al. 2017). Although study designs varied, improvements in FEV 1 percent predicted versus placebo appeared to be greater with tiotropium 5mg (peak 1.64-6.52%; trough 0.83-4.44%) and tiotropium 2.5mg (peak 3.11-7.70%; trough 2.35-5.05%) than LTRA (FEV 1 [peak/trough not specified] 0.73-2.50%). The percentage of patients reporting AEs was comparable for tiotropium and LTRA versus their respective placebo groups. CONCLUSIONS: This literature review suggests that tiotropium may provide greater improvements in FEV 1 than LTRA as add-on to ICS in pediatric patients with asthma, with reporting of AEs comparable with placebo.
TA Respiratory Diseases, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 5 Medicine Operations, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 6 Klinik fur Kinder und Jugendmedizin, Bochum, Germany. RATIONALE: This literature review compares the reported efficacy of tiotropium and leukotriene receptor antagonists (LTRAs) as add-on to ICS in children and adolescents with asthma. METHODS: We searched PubMed for manuscripts comparing LTRAs with placebo, as add-on to ICS, for > _4 weeks in patients with asthma aged 5-18 years, published post-July 2014 (studies published prior were included within two systematic reviews). Results were compared with data from tiotropium trials in pediatric patients. RESULTS: We included two systematic reviews with meta-analyses (Zhao et al. 2015 , a network meta-analysis of 35 trials; Castro-Rodriguez et al. 2010, a review including five studies relevant to this analysis). A literature search identified one additional relevant LTRA RCT (Stelmech et al. 2015; n576) . Four tiotropium trials were included: two compared tiotropium with placebo as add-on to at least ICS (Hamelmann et al. 2016; Vogelberg et al. 2018) ; two compared tiotropium with placebo as add-on to ICS plus > _1 additional controller (Hamelmann et al. 2017; Szefler et al. 2017) . Although study designs varied, improvements in FEV 1 percent predicted versus placebo appeared to be greater with tiotropium 5mg (peak 1.64-6.52%; trough 0.83-4.44%) and tiotropium 2.5mg (peak 3.11-7.70%; trough 2.35-5.05%) than LTRA (FEV 1 [peak/trough not specified] 0.73-2.50%). 4 University of Pennsylvania, Philadelphia, PA. RATIONALE: According to a consensus statement from the American Academy of Pediatrics, American Academy of Family Physicians and American College of Physicians, adolescents with special health care needs should receive developmentally appropriate health care services as they move to adult care. Adolescents with difficult to control asthma, an already vulnerable group, may face challenges as they transition to independent living, including adapting to new environments, keeping up with medications, and visiting doctors independently of their caregivers. According to the guidelines, providers should assess transition readiness in an effort to identify areas where education can be provided to facilitate a smooth transition to self-management and independent living. As a quality improvement measure, we administered the Transition Readiness Assessment Questionnaire (TRAQ) to identify areas where patient education can be provided in our adolescent and young adults with asthma on omalizumab, a medication administered under medical supervision for those who have failed more routine asthma treatment. METHODS: During their outpatient visit for omalizumab administration, a sample of patients between the ages of 16-21 filled out the TRAQ, a validated transition readiness questionnaire. Responses were scored from 1-5, with 5 signifying self-management. Numbers were averaged in each category. RESULTS: Of the 11 adolescents who filled out the survey, the lowest scoring category was ''Appointment Keeping'' and the highest scoring was ''Talking with Providers.'' Lowest scoring areas were questions referencing health insurance coverage. CONCLUSIONS: Further intervention includes providing education about health insurance coverage for adolescents and young adults as they transition to independent living.
